A detailed history of O'Brien Greene & Co. Inc transactions in Novartis Ag stock. As of the latest transaction made, O'Brien Greene & Co. Inc holds 5,698 shares of NVS stock, worth $623,247. This represents 0.2% of its overall portfolio holdings.

Number of Shares
5,698
Previous 5,574 2.22%
Holding current value
$623,247
Previous $539,000 12.43%
% of portfolio
0.2%
Previous 0.18%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$92.57 - $107.37 $11,478 - $13,313
124 Added 2.22%
5,698 $606,000
Q2 2023

Aug 15, 2023

SELL
$92.52 - $104.91 $1.03 Million - $1.17 Million
-11,148 Reduced 66.67%
5,574 $563,000
Q2 2023

Jul 20, 2023

BUY
$92.52 - $104.91 $1.03 Million - $1.17 Million
11,148 Added 200.0%
16,722 $1.69 Million
Q4 2022

Feb 02, 2023

SELL
$75.55 - $92.52 $871,695 - $1.07 Million
-11,538 Reduced 67.43%
5,574 $506,000
Q3 2022

Nov 09, 2022

BUY
$74.61 - $87.26 $851,150 - $995,462
11,408 Added 200.0%
17,112 $1.3 Million
Q4 2021

Feb 08, 2022

BUY
$79.7 - $88.13 $10,361 - $11,456
130 Added 2.33%
5,704 $499,000
Q4 2018

Feb 27, 2019

BUY
$73.66 - $82.02 $410,580 - $457,179
5,574 New
5,574 $478,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $235B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track O'Brien Greene & Co. Inc Portfolio

Follow O'Brien Greene & Co. Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of O'Brien Greene & Co. Inc, based on Form 13F filings with the SEC.

News

Stay updated on O'Brien Greene & Co. Inc with notifications on news.